Loading...

Armata Pharmaceuticals, Inc.

ARMP•AMEX
HealthcareBiotechnology
$1.33
$0.04(3.10%)

Armata Pharmaceuticals, Inc. (ARMP) Stock Overview

Explore Armata Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-100.00%
↓ 100.00%
Profit Growth
$-0.52
↑ 72.60%
EPS Growth
$-0.52
↑ 72.77%
Operating Margin
-4393.06%
↓ 3.78%
ROE
37.53%
↑ 72.60%
Dividend Yield
0.00%
Analyst Recommendations data is not available for ARMPAnalyst Recommendations details for ARMP are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

CEO

Dr. Deborah L. Birx M.D.

Employees

60

Headquarters

4503 Glencoe Avenue, Marina del Rey, CA

Founded

1994

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.